New drug trial offers hope for children with rare, treatment-related cancers
NCT ID NCT05656248
Summary
This study is testing the drug CPX-351 in patients under 22 years old who have developed secondary myeloid neoplasms, which are blood cancers that can occur after previous cancer treatments or due to genetic conditions. Participants receive up to two cycles of CPX-351 to try to achieve remission, followed by a stem cell transplant. The main goals are to see how well the drug works, how safe it is, and how patients survive after this combined treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
Explore the condition pages connected to this study.